A retrospective study that examined younger (60–75 years) AML patients treated with HMA + VEN did not show any difference in CR rates and median overall survival (OS), in case of NPM1, TP53, and FLT3-ITD mutant AML compared to IC [25]. This evidence concerns the gene TP53 and acute myeloid leukemia.